中文 | English
Return
Total: 19 , 1/2
Show Home Prev Next End page: GO
Author:(Jumei SHI)

1.Using the pathology report in initial treatment decisions for diffuse large B-cell lymphoma in the era of precision medicine:reports from the 57th American Society of Hematology annual meeting

Xiaojing HU ; Jumei SHI ; Bojie DAI

Journal of Leukemia & Lymphoma 2016;25(3):144-149

2.Maintenance therapy for multiple myeloma in the era of novel agents:reports from the 57th American Society of Hematology annual meeting

Ruixue YANG ; Yi TAO ; Jumei SHI

Journal of Leukemia & Lymphoma 2016;25(1):33-38

3.Progress in diagnosis and treatment of mantle cell lymphoma

Gege CHEN ; Jumei SHI ; Yiwen ZHANG

Journal of Leukemia & Lymphoma 2016;25(10):637-640

4.Clinical management of the multiple myeloma: reports from the 56th American Society of Hematology annual meeting

Ruixue YANG ; Yi TAO ; Jumei SHI

Journal of Leukemia & Lymphoma 2015;24(1):37-42

5.The hemophilias and their clinical management: reports in the 55th ASH annual meeting

Xiaojing HU ; Jun HOU ; Jumei SHI

Journal of Leukemia & Lymphoma 2014;23(2):75-78

6.Multiple myeloma:from diagnosis to staging

Ruixue YANG ; Lu GAO ; Jumei SHI

China Oncology 2014;(10):727-731

7.Progress in iron chelators: the report of the 53rd annual meeting of American Society of Hematology

Xiaojing HU ; Jun HOU ; Jumei SHI

Journal of Leukemia & Lymphoma 2012;21(2):73-76

8.Status of proteasome inhibitors in the treatment of multiple myeloma

Guang YANG ; Yi TAO ; Jumei SHI

Journal of Leukemia & Lymphoma 2013;22(1):38-41

9.Progress of cellular and vaccine immunotherapy in multiple myeloma

Jun HOU ; Yuanyuan KONG ; Fenghuang ZHAN ; Jumei SHI

Journal of Leukemia & Lymphoma 2017;26(2):86-90

10.Checkpoint inhibition in myeloma

Yiwen ZHANG ; Dandan YU ; Fenghuang ZHAN ; Jumei SHI

Journal of Leukemia & Lymphoma 2017;26(2):78-82

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 19 , 1/2 Show Home Prev Next End page: GO